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Available online 19 February 2019Protein-protein interaction (PPI) is a hot topic in clinical research as protein networking has a major impact in
human disease. Such PPIs are potential drugs targets, leading to the need to inhibit/block speciﬁc PPIs. While
small molecule inhibitors have had some success and reached clinical trials, they have generally failed to address
the ﬂat and large nature of PPI surfaces. As a result, larger biologicswere developed for PPI surfaces and they have
successfully targeted PPIs located outside the cell. However, biologics have low bioavailability and cannot reach
intracellular targets. A novel class -hydrocarbon-stapled α-helical peptides that are synthetic mini-proteins
locked into their bioactive structure through site-speciﬁc introduction of a chemical linker- has shown promise.
Stapled peptides showanability to inhibit intracellular PPIs that previously have been intractablewith traditional
small molecule or biologics, suggesting that they offer a novel therapeutic modality. In this review, we highlight
what stapling adds to natural-mimicking peptides, describe the revolution of synthetic chemistry techniques and
how current drug discovery approaches have been adapted to stabilize active peptide conformations, including
ring-closing metathesis (RCM), lactamisation, cycloadditions and reversible reactions. We provide an overview
on the available stapled peptide high-resolution structures in the protein data bank,with four selected structures
discussed in details due to remarkable interactions of their staplewith the target surface.We believe that stapled
peptides are promising drug candidates and open the doors for peptide therapeutics to reach currently
“undruggable” space.
© 2019 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
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Drug discovery approaches targeting protein-protein interactions
(PPIs) has been fast-tracked over the present decade to deliver success-
ful new drug leads and opens an expansive range of new therapeutic
targets that were previously considered “undruggable”. This accelera-
tion in PPI-based drugs is due to improved screening and design
technologies, shortening the time between drug discovery to drug reg-
istration and changing pharmaceutical economic delivery [1]. More-
over, most human diseases are underpinned by a complex network of
PPIs, (for example hubs such as p53), which underscores the need to
understand PPIs not only on a clinical level, but also on molecular
level. In this respect, the “omics” such as, genomics, RNA, proteomics
and metabolomics can accumulate huge volumes of data aiming at
targeted and personalized medicine [2,3].
All of the data, in addition to structural and screening-based
approaches, have signiﬁcantly expanded our understanding on PPI in-
terfaces that were previously highly challenging and difﬁcult to target,
as these interacting surfaces are shallow or ﬂat, non-hydrophobic and
large (1500-3000 Å). In addition, PPI surfaces differ in their shape and
amino acid residue composition, particularly the hot spots that are es-
sential during binding protein partners; making small-molecules enti-
ties unlikely as protein therapeutics [4–8]. Moreover, the discovery of
innovative and drug lead molecules with the expected biological
activity and pharmacokinetics is the main aim of medicinal chemistry.
Therefore, the application of ‘follow-on’-based strategy has always
been one of themost effective approaches that lead to promising bioac-
tive molecules. Conformational restrictions or “rigidiﬁcation” is one of
these strategies that has been widely used to overcome ligand ﬂexibil-
ity, which suffer from entropic penalty upon binding to the target sur-
face [9]. The restriction strategy has two major advantages: ﬁrstly, it
could increase the potency of the drug-like agent by stabilizing a favor-
able binding conformation, reducing the entropic penalty on binding to
the target and decrease its degradation byhinderingmetabolically labile
sites or introducing a fused-ring structure; in addition to improve iso-
form selectivity or speciﬁcity toward targets. Secondly, controlling li-
gand conﬁrmation could improve afﬁnity on the atomic level without
requiring additional interactions [9,10].
There are two types of drugs generally available on the market: tra-
ditional small-molecule drugs with molecular weight of b500 Da and
high oral bioavailability but low target selectivity; and biologics that
are typically N5000 Da (such as insulin, growth factors, erythropoietin
(EPO) and engineered antibodies) that have limited oral bioavailability,
poor membrane permeability andmetabolic instability. As a result such
medications are typically delivered by injection. However, biologics
have extremely high speciﬁcity and afﬁnity for their targets due to the
large area of interaction with their targets [1,11]. Despite the success
of both drug classes in treating different diseases, there remains an op-
portunity to offer a class of molecules to ﬁll the gap inmolecular weight
between the existing two classes (Smallmolecules b500…Peptides…Bi-
ologics N5000 Da) and merge some of the advantages of small-
molecules and biologics in terms of oral bioavailability, cell penetration
and cheaper manufacturing costs. This class could be considered to be a
next generation therapeutic class that precisely targets PPIs and is based
upon hydrocarbon-stapled α-helical peptides. Fig. 1 represents the
three classes of targeted drugs based on their molecular weight.
In this review we will focus on hydrocarbon-stapled α-helical pep-
tides and their use as potential drugs. Hydrocarbon α-helical peptides
are synthetic mini-proteins locked into their bioactive α-helix second-
ary structure by site-speciﬁc insertion of a synthetic chemical staple
linker or “brace”. Stapled peptides show a greatly improved pharmaco-
logic performance, increased afﬁnity to their target, resistance to pro-
teolytic digestion, and afford high levels of cell penetration via
endocytic vesicle trafﬁcking [5,12–14].
In this review we will discuss what stapling adds to this class of in-
hibitors in terms of stability, bioactivity and cell penetration, thechemistry behindpeptide stapling and provide anoverviewon some se-
lected successful examples of peptide-based drugs to underline their
importance. Lastly, we will underline four exclusive stapled-peptides
targeting PPIs, in which their staple makes an intimate interaction
with the target interface, in order to reveal the role of stapling on pep-
tide binding and their inhibition of PPIs.
2. Why Stapled Peptides?
Helical peptides are one of the two main secondary structural ele-
ments in PPI interfaces, (in addition to β-sheets) and play a central
role in protein functionwithin the cell. Often these elements are not sta-
ble in conformation in the absence of a complete protein fold. Addition-
ally, peptides are sensitive to proteolysis by peptidases reducing their
half-life (down to minutes), impacting their ability to penetrate cell
membranes – all of which makes native peptides poor drug candidates
[14–16]. Notwithstanding, one main feature that makes peptides good
drug candidates is their ability to bind large and relativelyﬂat target sur-
faces efﬁciently and speciﬁcally, which is a requirement in the majority
of intracellular therapeutically relevant PPIs. This makes peptides as an
attractive target for drug development and enables their transition into
the clinic [5,17]. The use of therapeutic peptides has grown explosively
over the last three decades, covering areas such as metabolic diseases,
oncology, and cardiovascular diseases [18]. From a dataset that was col-
lected recently on March 2018 and based on previously released data-
base report by Peptide Therapeutics Foundation, of 484 therapeutic
peptides, 60 have been approved in the United States, Europe, and/or
Japan, 155 peptides are in clinical development and 50% are currently
in Phase II studies (Fig. 2) [18].
Massive efforts and optimizations have been conducted in order to
overcome the limitations above. To impose a peptideα-helix conforma-
tion (thereby improving their binding afﬁnity toward their target pro-
tein) non-native amino acids were used in the peptide that lie on the
same helix face. These non native amino acids are then linked together
or “stapled” through side-chains that can be covalently bonded [16,19].
In order to address a second issue, to synthesize peptides with resis-
tance toward proteases, non-peptide (such as cyclic tripeptides, hetero-
cyclic or other organic constraints) are inserted into a peptide sequence
to maintain the peptide backbone in a linear saw-toothed strand struc-
ture [20–23]. These chemical modiﬁcations have evolved over time
since the ﬁrst all-hydrocarbon stapling by Verdine and colleagues in
2000, who produced a large series of α, α-disubstituted non-natural
amino acids bearing oleﬁn tethers (Fig. 3a). His work was an extension
of Blackwell and Grubbs, who were the ﬁrst to use Grubbs catalysts to
make a cross-link between O-allylserine residues on a peptide template
(Fig. 3b).Walensky provided the bridge between chemistry and biology
by generating hydrocarbon- stapled BH3 peptide helices, targeting BCL-
2 homology 3 domains responsible for the interactions of BCL-2 family
proteins thatmainly regulate cellular life anddeath at themitochondrial
level. This stapled peptide not only showed a higher stability and re-
markable resistance to proteolysis, but also high cellular permeability
[19,24,25]. The details of stapled-peptide chemical synthesis will be
discussed in detail in Section 3.
Interestingly, peptides could be differentiated from proteins by their
size (50 amino acids or less) but have similar speciﬁcity toward their
targets as biologics. However, peptides are more potent binders to
PPIs interfaces, because of their ability to bind large protein surfaces
with great selectivity and less toxicity when compared to small mole-
cule drugs, which often produce toxic metabolites. In contrast to small
molecules, peptides are degraded into amino acids, which are in turn
not toxic or harmful for cells [1,26]. Furthermore, peptides have lower
manufacturing costs and are more stable at room temperature (unlike
recombinant antibodies and engineered proteins). Finally, as non-
natural amino acids are the building blocks of peptides, the opportunity
to produce diverse scaffolds with modiﬁed chemical and functional






















Fig. 1. The three classes of targeted medicines. The traditional small- molecules inhibitors were the ﬁrst class discovered to inhibit different PPIs surfaces with MW of b500 Da and high
bioavailability. Most of the biologics, the second class of PPI targeted molecules, have a MW of N5000 Da (eg. antibodies and growth hormones) aimed to overcome a broad range of
diseases. Stapled α-helix peptides as a class address this gap in MW between small molecules and biologics, aiming to combine the oral bioavailability of small-molecules with the
high speciﬁcity of biologics toward the target protein.
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residues at or near the binding interface are necessary to achieve a suc-
cessful interruption of PPI partner proteins in vivo. Peptide design
is based upon the ligand-target pair, in that the ligand retains its
α-helicalmotif and is docked into shallow cleft surface of the target pro-
tein. Thus, stapled peptide inhibitors represent “dominant-negative”
versions of the docking helix [5]. The peptide is then optimized by se-
quence modiﬁcation “or stapling” to improve cell penetration and pep-
tide efﬁcacy to compete with the intracellular ligand protein, and it is
crucial to position the cross-linking amino acids in such way that the
targeted interface remains intact [5]. After evaluating the cellular uptake
of the stapled peptides using live confocalmicroscopy, a broad spectrum
of cellular and in vivo studies are applied to examine the therapeutic ac-
tivity of the stapled peptides toward their targets. A ﬂow-chart in Fig. 4
summarizes the development process of therapeutic peptides for bio-
logical study, fromvirtual design to in vivomousemodel analysis. Exam-
ples of stapled peptide created through the use of high-resolutionFig. 2. Statistical representation of therapeutic peptides until March 2017. The numbers are ind
were producedwith development activity regulatory approval frommajor pharmaceuticalmark
32% are in clinical trials and further classiﬁed as phases I, II, III and pre-registered. The highest
proval. The lowest percentage 2% is the “Withdraw” category that refers to previously approvestructures are SAHBA, based on BH3 domain of proapoptotic BID protein
[25], SAH-p53, based on the p53-MDM2 interaction interface [29], SAH-
gp41 double stapling peptide, targeting the HIV-1 virus and Enfuvirtide,
the ﬁrst decoy HR2 helix fusion inhibitor [30]. If the proteins involved in
the PPIs of interest have no previous structures, Ala-scanning or residue
conservation “in situmutagenesis” can be used as a starting point to po-
sition the staple. If this information is also not available, then synthesiz-
ing and screening all stapling positions is advisable [5].
3. Chemical Synthesis of Stapled Peptides
As the synthesis of bioactive-stapled peptides started to widen, the
approaches used also branched and allowed stapled peptides to be
applied for various purposes such as target binding analyses, structure
determination, proteomic discovery, signal transduction research, cellu-
lar analyses, imaging, and in vivo bioactivity studies [31]. Solid-phase
peptide synthesis (SPPS) is a standard and commonly used chemicalicated in percentage at each category with a total number of 484 medicinal peptides that
ets as, theUnited States, Europe, and Japan. From these peptides 12%were approved,while
percentage (54%; “Discontinued”) category encompasses peptides terminated before ap-
d peptides that are no longer available in the market [18].
O O O O
CH3H3C CH3 H3C
O-allyl Serine Residues (RCM)
α,α-disubstitution, Olefin tether (RCM)a) 
b) 
Fig. 3. Ruthenium-catalyzed ring-closing metathesis (RCM) reaction for peptides stapling was a) published for the ﬁrst time by Verdine and Schafmeister in 2000 by engaging α,α-
disubstituted non-natural amino acids harboring all-hydrocarbon tethers [19]. Their work was a continuation of b) Blackwell and Grubbs work in 1998 [24]; who performed
ruthenium-catalyzed oleﬁn metathesis for macrocyclisation of synthetic peptides using a pair of O-allylserine residues in a metathesis reaction.
266 A.M. Ali et al. / Computational and Structural Biotechnology Journal 17 (2019) 263–281procedure to synthesize α-helix peptides. The ﬁrst required entity to
start stapled peptides synthesis is a stock of non-natural amino acids
building blocks with a variable length of the terminal oleﬁn tethers.
The choice of the non-natural amino acids will deﬁne the length, struc-
ture and the chemical functionalities of the stapled linker [14,32].
The helix backbone amino acids are protected with a base-labile
ﬂuorenylmethoxycarbonyl (Fmoc) to obtain N- α -Fmoc-protected
amino acids, which are often offered with acid-labile side chain
protecting groups that vary between the 20 amino acids. The side
chain protecting groups of each amino acid for standard SPPS of stapled
peptides are indicated in Table 1. After the synthesis of non-natural
amino acids and peptide elongation during SPPS; ring-closingmetathe-
sis (RCM) of the stapled is performed.Fig. 4. Workﬂow of all hydrocarbon-stapled peptides generated for biological investigation
possibilities based on previous reported structures, followed by in vitro biochemical, structura
the target protein interface utilizing biophysical assays and crystallization trials. Potent bin
confocal microscopy. Lastly, successful peptides are subjected to a broad spectrum of cellular aSPPS has been automated using Fmoc chemistry to become an
efﬁcient and reliable method to yield hydrocarbon-stapled peptides of
single or double staplingwith different functionalities and experimental
applications. However, SPPS has two main complications: First,
efﬁciency is limited in longer peptides (N50 residues). These are more
usually expressed using recombinant DNA technology, due to the un-
availability of the N-terminal amine of the non-natural amino acids
(mostly after naturally bulky residues like arginine or β- branched
amino acids (valine, isoleucine, and threonine)). Additionally, extension
of deprotection and coupling times with fresh reagent may be required
in the synthesis of larger peptides. The second complication is that
cross-reaction or progressive inaccessibility of the N-terminus due to
on-resin aggregation could occur [31–33].. Computational designation of the peptides including in-situ mutagenesis to screen all
l, and functional studies compromising peptides binding afﬁnities measurements toward
der peptides will be further tested for their cellular uptake and permeability using live
nd in vivo analyses, using mouse models of the studied disease.
Table 1
The acid-labile side chain protecting groups used in SPPS synthesis of stapled peptides.
Amino acid Three letters-code Side chain protecting group
Alanine Ala N/A
Cysteine Cys Trityl (Trt)
Aspartic acid Asp tert-Butyl (OtBu)
Glutamic acid Glu tert-Butyl (OtBu)
Phenylalanine Phe N/A
Glycine Gly N/A
Histidine His Trityl (Trt)
Isoleucine Ile N/A
Lysine Lys tert-Butoxy (Boc)
Leucine Leu N/A
Methionine Met N/A
Asparagine Asn Trityl (Trt)
Proline Pro N/A
Glutamine Gln Trityl (Trt)
Arginine Arg Pentamethyldihydrobenzofurane (Pbf)
Serine Ser tert-Butyl (OtBu)
Threonine Thr tert-Butyl (OtBu)
Valine Val N/A
Tryptophan Trp tert-Butoxy (Boc)
Tyrosine Try tert-Butyl (OtBu)
267A.M. Ali et al. / Computational and Structural Biotechnology Journal 17 (2019) 263–281Initial screening of different types of stapling is required if structural-
based knowledge is not available. As indicated previously in Section 2,
prediction software can suggest the peptide α-helix template, then a
group of constructs with differentially localized staples can be gener-
ated to determine the optimal staple placement. However, if the target
PPIs interface is structurally well characterized, this structural data can
be used for computational docking and designing of the desired tem-
plate peptide to generate a panel of peptides with diverse staplinga)
i,i+4        













Fig. 5. a) The common stapling insertion positions for α-helix peptides. Combinations of two
hydrocarbon linker. Employing S5/S5 at position i,i + 4 is the most common stapling positio
either S8/R5 or S5/R8. Synthetic chemistry evolved to introduced i,i + 3 and i,i + 11 as new p
designed amino acids used to introduce all-hydrocarbon staples into peptides. All possess
conﬁguration and different length at the alkenyl chain.type and position. Stapling techniques could be divided into
one-component or two-component stapling techniques, based on the
side-chain linking reaction. During one-component stapling a direct
bond will be formed between two non-natural amino acids side-
chains, whereas two-component stapling involves a separate bifunc-
tional linker to connect the side-chains of two non-natural amino
acids [14]. The most commonly used technique for stapling is the one-
component stapling technique - employing S-pentenylalanine at i,i +
4 positions for one turn stapling or combining either R-octenylalanine/
S-pentenylalanine or S-octenylalanine/R-pentenylalanine at i,i + 7 po-
sitions. Other spacings for staplingwere also accomplished upon chem-
ical optimization, including i,i + 3 and i,i + 11 [14,31,32,34]. The
common stapling positions are shown in Fig. 5.
There are several chemical procedures to enclose or stabilized
the all-hydrocarbon linker into α-helix peptide such as, ring-closing
metathesis, lactamisation, cycloadditions, reversible reactions and
thioether formation. A brief summary for each methodology and some
literature examples is provided below.
3.1. Ring-Closing Metathesis (RCM)
Blackwell and Grubb were the ﬁrst to apply alkene ring-closing me-
tathesis as a peptide stapling method. They described solution-phase
metathesis, followed by hydrogenation of hydrophobic heptapeptides
containing either O-allyl serine or homoserine residues with i,i + 4
spacing (Fig. 6) [24]. Their study emphasized the feasibility of metathe-
sis on helical peptide side-chain. Later in 2000, Schafmeister and his
colleagues managed to conduct metathesis stapling usingα,α-disubsti-
tuted amino acids carrying oleﬁnic side-chains of different lengths and
stereo-chemistry on solid phase prior to peptide cleavage from resin,i,i+3












non-natural amino acids S5, R5, S8 and R8 are used for different positions of stapling the
n on the same face of helix turn. For i,i + 7 position, two combinations could be applied
ossible positions for stapling in addition to double-stapling. b) The structures of the four
an α-methyl group (Me) and an α-alkenyl group, but with opposite stereochemical
Ac-EWAE NH AAAKFL HN AHA
(  )6(  )3
Ac-EWAE NH AAAKFL HN AHA
(  )6(  )3
Fig. 6. RCM or ring closing metathesis reaction for synthesis of the all-hydrocarbon stapled peptide reported by Schafmeister et al. 2000, which increase peptides helicity as found by
circular dichroism (CD) [19].










Fig. 7. A Lactamisation study that was conducted by Fairlie and co-workers on penta and hexa-peptides in order to optimize lactam stapling between Orn/Lys and Asp/Glu residues. It
wasn't the ﬁrst study for lactam optimization; however, the group was abled to systematically and quantitatively found the shortest peptide with retained helicity in water as judged
by CD [39].
268 A.M. Ali et al. / Computational and Structural Biotechnology Journal 17 (2019) 263–281producing a large series of α, α-disubstituted non-natural amino
acids S5, R5, S8 and R8 bearing oleﬁn tethers that were used for dif-
ferent stapling positions of the hydrocarbon linker as shown in Fig. 5.
The end products were a collection of i,i + 4/7 peptides and they
found that i,i + 7 stapled peptides have higher helicity and stability
over native and non-stapled peptides [19]. BID BH3 peptides that
bind to BCL-2 family proteins are a successful product of metathesis
stapling by Walensky et al. and they showed that the optimized sta-
pled peptide has more stability than the native one, provoke apopto-
sis in leukemia cells, and inhibit the growth of human leukemia
xenografts in mice [25]. p53-MDM2/MDMX dual inhibitor stapled
peptides were reported by Sawyer and co-workers, who provided
promising in vitro data for binding afﬁnity, cellular activity and sup-
pression of human xenograft tumors in animal models [35]. These
ﬁndings are the basis of p53 optimized stapled peptides that have
enter clinical trials.
Further, Verdine et.al introduced a unique form of multiple stapling,
called stitches, in which two hydrocarbon staples immediately follow
one another. This technique requires the use of the amino acid bis-
pentenylglycine (B5) that forms a junction between the two staples
and emerges from a common residue in the peptide. There are many
possible combinations of stereochemistry and linker length in such a
system. Various stitch combinations were studied rigorously and two
systems, i,i+ 4 + 4 (S5 + B5 + R5) and i,i+ 4 + 7 (S5 + B5 + S8),
appeared the most effective for helix stabilization. A peptide with the
latter stitch construction was found to have superior helicity and cell
penetration compared with an i,i+ 7 stapled analogue [36].
Optimization and extensive development in hydrocarbon stapling
approach allow stapling at i,i + 3/4/7 spacings. Regardless of the many
examples in literature of successful hydrocarbon stapling, there is no
guarantee that stapling will enhance peptide stability, cell penetration
and binding to the target. Extensive optimization is needed in order to





Fig. 8.Optimized CuAAC-stapled peptide was successfully developed to inhibit the BCL9 oncoge
that ﬁve units of methylene was optimal stapled peptide for BLC9 inhibition [43].3.2. Lactamisation
Stabilization of an α-helix can also be accomplished through side-
chain intramolecular amide-bond formation between i,i + 4 spaced
amine- and carboxy-side chain amino acids. Lactamisation was ﬁrst
studied by Felix et al. in 1988 [37], in which they coupled Lys and Asp
residues side-chains in a growth hormone releasing factor short conge-
ner. Growth hormone helicity and activity were conserved post
macrocyclisation,whichweremeasured by NMR and circular dichroism
(CD) (bothmethods that can be used for analyzing the secondary struc-
ture of peptides and proteins in aqueous solution) [38]. Since then, nu-
merous studies applied lactamisation and amide linkage on different
chain length and positions, with the intention of generating a stable
helix for different systems. For example, a lactam stapling optimization
study on penta/hexapeptides between Orn/Lys and Asp/Glu residues,
carried out by Fairlie and co-workers (Fig. 7) [39], examined the
shortest possible peptide with α-helix reinforced structure in water.
Subsequently, the Fairlie group applied their ﬁnding on different tar-
gets, including inhibition of respiratory syncytial virus with double
lactam-stapled peptide in 2010 with improved antibacterial activity.
Another target was the nociceptin hormone studied in the same year,
in which lactam-stapled peptide induced higher ERK phosphorylation
in mouse cells and thermal analgesia [22]. Norton and co-workers also
examined several Asp/Lys lactam-stapling combinations at i,i + 4 posi-
tion on μ-conotoxin KIIIA, a natural peptide frommice that acts as a po-
tent analgesic by binding voltage-gated sodium channels (VGSCs),
where they found that stapled peptides have different level of helicity
and inhibitory activity on variable VGSC when examined in Xenopus
laevis oocytes [40]. From a chemical perspective, lactam stapling is
easier to obtain and incorporate due to proteogenic amino acids
when compared to other stapling techniques, which require non-
proteogenic amino acids. A drawback is that an extra orthogonal






nic interaction. After screening different stapling length,Wang and co-workers concluded















Fig. 9. Schultz and co-workers described an i,i + 7 staplingmethodology using disulphide bridges between D and L amino acids bearing thiol-side chains. The amino acidswere connected
with acetamidomethyl (Acm) protecting groups, deprotected and then oxidisedwith iodine to give a disulphide stapled peptide. CD spectra of disulphide stapled peptides exhibited a high
level of α-helicity in comparison to the Acm-protected precursors that were signiﬁcantly less helical [45].
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technique should be mentioned, which is the lactamisation stapling of
Lys and Asp residues. Stapling at these residues is only compatible
with i,i + 4 spacing with longer linkages that required modiﬁed
amino acids with longer side-chains. From a biological point of view,
and based on a large number of studies on peptide lactamisation, this
stapling technique can create therapeutic peptides with superior bioac-
tivity. However, most of their targets are either extracellular or
membrane-bound, suggesting that lactamisation stapling has no poten-
tial to improve cell penetration [14].3.3. Cycloadditions
Cu (I)-catalyzed azide–alkyne cycloaddition (CuAAC) or the “Click”
reaction is another mechanism of peptide stapling, it is also known as
biocompatible ligation technique [41]. The ﬁrst research group who
applied CuAAC to generate α-helix structures between i,i + 4 spacing
within peptides were Chorev, D'Ursi and co-workers in 2010, based on
parathyroid hormone-related peptide [42]. Subsequently, many
groups used this type of stapling in order to determine the best linker
length, including Wang and co-workers, who found that ﬁve methy-
lene units were the optimum staple length to inhibit the oncogenic
BCL9-beta-catenin PPI (Fig. 8). A further signiﬁcant result, reported
by the same team, of the Click reaction was based on triazol-
position screening along a peptide targeting the same oncogenic pro-
tein, beta-catenin, to generate a library of stapled peptides exhibiting
different in vitro binding afﬁnities and helicity [43]. Madden et al.,
used an unusual cycloaddition via UV-induction between tetrazoles
and alkenes to hinder p53-MDM2/MDMX interaction. The stapling re-
action took place between i,i + 4 by exposing unprotected linear pep-
tides to UV irradiation in solution, which resulted in stapled peptides
displaying higher afﬁnity toward MDM2/MDMX in a ﬂuorescence po-
larization assay (FP). However, these peptides were not cell perme-
able. This problem could be overcome by modifying a number of the
peptide amino acids to Arg, whereby cellular uptake and moderate
p53 activity were achieved [44]. Generally, stapling with cycloaddition
chemistry shows a promising future, in that triazol- stapled amino
acids are accessible and CuAAC is well established. In the example of
UV-induced reactions, the method is simple to apply but requires










Fig. 10. Thioether stapling method was reported by Brunel and Dawson in 2005. They demonst
stapled peptide that inhibited HIV fusion using the gp41 epitopes as template for peptide synt3.4. Reversible Reactions
Using disulphide bridges between two Cys residues as stapling
technique was ﬁrst introduced by Schultz et al. at i,i + 7 positions.
The disulﬁde bridge was formed between D and L-amino acids having
thiol-side chain, followed by the addition of acetamidomethyl (Acm)
protecting groups, protection and oxidization with iodine (Fig. 9).
The helicity of disulﬁde-stapled peptides was higher when compared
with the Acm-protected precursors, as displayed in CD spectroscopy
[45]. Although disulﬁde stapling was the earliest reported stapling
technique, little was concluded due to the instability of the disulphide
stapled peptides in reducing environments, which restrict their appli-
cation in intracellular targets. However, stapling with oxime linkages
[46] and two-component bis-lactam and bis-aryl stapling techniques
[47,48] were found to be superior to the analogous disulphide sta-
pling. Recently, Wang and Chou demonstrated the possibility of sta-
pling and macrocyclization using thiol-en between two Cys residues
an α, ω-diene in high yields (an unsaturated hydrocarbon containing
two double bonds between carbon atoms), which allowed stapling of
both expressed/unprotected and synthetic peptides. This group ap-
plied their discovery to the p53-MDM2 PPI and successfully synthe-
sized stapled peptides with both i,i + 4 and i,i + 7 linkages,
applying this method in the stapling of large peptides and proteins.
Development in reversible stapling is slow, but efforts in applying
this method in biological dynamic covalent chemistry are under active
investigation.3.5. Thioether Formation
The reaction between Cys thiol and alpha-bromo amide groups has
been developed as a protocol for peptide stapling byBrunel andDawson
[49]. This linkage was designed to mimic the ring size of previously re-
ported lactam staples, but a thioether link was hosted into gp41-
peptide epitopes as an approach to establish an HIV vaccine. Successful
staples were created in both i,i + 3 and i,i + 4 linkages and a peptide
with i,i + 3 stapling (Fig. 10) demonstrated a higher helicity over
unstapled and lactam-stapled peptides i,i+4.Moreover, after optimiza-
tion the stapled peptide bound to a gp41-speciﬁc antibody (4E10)more
effectively than the uncyclised peptide [50]. Theseﬁndings illustrate the
efﬁciency of thioether stapling with shorter distance i.e. i,i + 3, while







rated the reaction of Cys thiol and alpha-bromo amide groups to report a i,i + 3 thioether
hesis [49].
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Interaction (PPI) in the PDB
The number of peptides entering clinical trials has increased over the
last 35 years, with an average peaking in 2011, when over 22 peptides/
yearwere successful in entering clinical development [18]. This evolved
from technology maturation and advances in synthetic chemistry and
puriﬁcation of peptides, in parallel with improvements in biophysical
and molecular pharmacological methods. However, there is a limited
number of high-resolution structures of staple peptides in complex
with their targets in the protein database (RCSB www.rcsb.org), as of
July 2018 [51]. There are 67 “stapled peptides” structures, of which 58
are based on X-ray diffraction (83%) and 9 on NMR studies (17%).
When limiting the analysis to Homo sapiens, our search found 43 struc-
tures, targeting a limited range of PPIs, of which the majority are of the
p53-MDM2/MDMX interaction, the BCL-2 family (including the MCL-1
BH3 domain), estrogen receptor and human immunodeﬁciency virus
type 1 (HIV-1). Other druggable interfaces of interest were kinases
[52,53], insulin [54], tankyrase-2 [55], growth factor receptor-bound
protein 7 (Grb7) [56], the Fc portion of human IgG [57], eIF4E protein
[58] and transducin-like enhancer (TLE) proteins [59]. MDM2 and its
homolog MDMX represent 18.6% of total X-ray structures in protein
data bank, which indicates their importance as the main negative regu-
lators of p53 (“The Guardian of the genome”) since it behaves as a hub
protein [60]. This escalation in stapled peptide drug discovery has
crossed over into the traditional focus upon endogenous human pep-
tides to include a broader range of structures identiﬁed through medic-
inal chemistry efforts. Not surprising, today over 150 stapled peptides
are in the active development of human clinical studies [18].
The analysis presented in Table 2 provides a list of the crystal struc-
tures belong to therapeutic stapled peptides, which mimic the native
peptides in complex with their target protein interfaces. The table also
gives an overview of the PDB structure code, name of stapled peptide
and biophysical assays that are used tomeasure the bindingdissociation
constant (Kd) of the stapled peptide to the target protein.
Not all staples interact with the target protein surface via commonly
known chemical interactions; instead they can induce conformational
changes to either the syntheticα-helix peptide or the target protein in-
terface, speciﬁcally the amino acids residues involved in PPIs. These
changes stabilize and ﬁx the helical peptide in a potent binding mode
within the target interface. A limited number of stapled peptides have
different interactions with their intracellular targets, which contributes
to their high speciﬁcity, stability and makes these peptides promising
target therapies for human diseases. Table 3 underlines the role of the
stapled linker in binding to the target protein surface and indicates if
it is involved in any interaction with the target surface residues via
Van der Waals, hydrogen/disulﬁde bonds or π-π interactions. All of
these interactions were inspected from the crystal structures of the sta-
pled peptides in complex with the target protein surfaces. Examples of
these peptideswill be discussed extensively in thenext sections to high-
light the evolution of medicinal chemistry techniques.
4.1. SAH-p53-8: Stapled p53 Peptide Binds Potently to Human MDM2
p53, the main tumor suppressor, which is mainly negatively regu-
lated by the E3 ubiquitin ligase MDM2. Although p53 is mutated or
inactivated in N50% of human cancers, the other 50% retain WT-p53.
Therefore, the p53: MDM2 PPIs is a promising and conﬁrmed target
for drug discovery and cancer therapy. This can be accomplished by dis-
covering a potent MDM2 binder in order to prevent its binding to p53
and thereby restore its biological function. In 2012, Baek and co-
workers were able to resolve a high-resolution structure of a stapled
peptide inhibitor in complex with MDM2 (SAH-p53-8 (PDB 3V3B))
[62]. This peptidewas synthesized following ring-closing oleﬁnmetath-
esis (RCM) at i,i + 7 stapling positions between residues Asn20 and
Leu26. As anticipated bymolecular dynamics (MD), the crystal structurerevealed an extended region of the helical peptide from residues 19–27
in the bound state that was not seen in other peptides with lower afﬁn-
ities toward MDM2. Moreover, the bound peptide induced minor
changes in MDM2, speciﬁcally at the side chain of Met62 (which folds
away from the p53 binding pocket, to make space for the staple),
Val93 (which shifts inside the binding pocket) and the side chain of
Tyr100 that is found in a “closed” form. However, the α-helix peptide
is located in the same position as the native helix of p53, orienting the
three residues critical for binding (Phe19, Trp23 and Leu26) in the cor-
rect location (Fig. 11). Remarkably, the aliphatic staple intimately inter-
acts with the protein and is located directly over theMet50-Lys64 helix
and contributes ca. 10% of the peptide-Mdm2 total surface contact
area. Additionally, the staple shields a H-bond between Trp23 and
Leu54 from solvent competition (Fig. 12). Two novel features were
discovered in the complex structure, ﬁrst an extended hydrophobic in-
terface of the staple linker with Leu54, Phe55, Gly58, and Met62 of
Mdm2. The second feature is that the staple displaced a common
water molecule present in most MDM2 structures, which forms
H-bonds with Gln59-N and Phe55-O. The later displacement likely en-
tropically stabilizes the complex during binding and contributes to
SAH-p53-8 tight binding as evidenced by an FP assay showing a Kd of
55 nM. Lastly, stapling increases peptide helicity during binding in rela-
tion to that of native p53 - inﬂuencing residue Leu26, which plays an
important role in MDM2 binding. Additionally, the researchers con-
cluded that the long stapling i,i + 7 enhanced helical conformation
and afﬁnity as suggested by previous studies [19]. Subsequent to the
discovery of SAH-p53-8, several stapled peptides, such as sMTide-02
[99] and ASTP-7041 [35], showed potent binding toward MDM2 with
Kd values of 34.35 and 0.91 nM, respectively. Additionally, both peptides
(in addition to VIP-84 (another stapled peptide targetingMDM2: p53))
showed cellular permeability when tested using a nanoBRET (Biolumi-
nescence Resonance Excitation Transfer) live cell assay. Screening vari-
ous lipid based formulations, the cellular uptake of VIP-84was shown to
be enhanced, aswell as its biological activity, whichwas linked to vesic-
ular or endosomal escape of the stapled peptide through the cell mem-
brane [100].
4.2. MDM2 Double Macrocyclization Stapled Peptide: Fast Selection
of Cell-Active Inhibitor
Following on from the SAH-p53-8 potent peptide inhibitor, Lau et al.
managed to synthesize a stapled peptide-E1 by applying a novel sta-
pling technique [64]. This technique is based on double Cu-catalyzed
azide–alkyne cycloaddition (CuAAC) and followed two-component
strategies, in that the staple and α-helix peptide are separated before
cyclisation. This was combined with click chemistry to generate a pep-
tide with variable functional staples. The team used the p53-MDM2 in-
teraction as a model, since that target has been well investigated as an
oncogenic therapy for cancerswith overexpressedMDM2. For optimum
inhibitor screening, and to ensure fast and easy selection for the best
peptide, cyclisation was conducted in situ and directly in primary cells
mediumusing a 96-well assay. This approach eliminated the extra puri-
ﬁcation step required in other two-component strategies and provided
a ﬁrst example of staplingwithin a biological environment. The ﬁrst sta-
pled peptide A1 was synthesized by linking diyne 1 to p53-derived
diazidopeptide A to produce A1 with 60% yield. Different peptide vari-
ants B-E were tested in situ to deﬁne a peptide with the highest p53 ac-
tivation, showing that the E+1 stapled peptide was the most potent
activator within cells. The binding afﬁnity of the E1 peptide was mea-
sured using two biophysical assays (FP and ITC) determining Kd values
of 7.5 ± 0.7 and 12 ± 3 nM, respectively. The crystal structure of E1-
MDM2 (17–108, E69A/K70A) complex at 1.9 Å resolution elucidated
the helical structure of E1 orienting the three hydrophobic key residues
(Phe19, Trp23 and Leu26) in the correct positioning for MDM2 binding
(PDB 5AFG), in a manner broadly similar to that of the p53 native pep-
tide (Fig. 13a). The bis (triazolyl) staple was discovered in an anti
Table 2
List of structural-resolved stapled peptides in complex with PPI targets from RCSB-PDB.
Target PDB ID Binding Assay Peptide Kd (nM) Ref.
X-ray NMR
Human MDM2/4 IYCR ITC p53-WT Residues (15–29) 600 [61] NA
3V3B FP SAH-p53-8 Stapled peptide 55 [62] NA
ITC 12
4UMN FP M06 Stapled peptide 63 ± 17.8 [63] NA
5AFG FP E1 Stapled peptide 7.5 ± 0.7 [64] NA
4UE1 FP YS-1 Stapled peptide 9.9 ± 1.5 [65] NA
4UD7 FP YS-2 Stapled peptide 7.4 ± 1.5 [65] NA
5XXK FP M011 Stapled peptide 6.3 ± 2.9 [66] NA
5VK0 – PMI – [67] NA
5VK1 – PMI – [67] NA
MCL-1/BCL-2 3MK8 FP MCL-1 SAHBD Stapled peptide 10 ± 3 [68] NA
5C3F FP BID-MM Stapled peptide 153 ± 12 [69] NA
SPR 107 ± 29
5C3G SPR BIM-MM Stapled peptide 460 ± 232 [69] NA
5W89 FP SAH-MS1-18 Stapled peptide 25 ± 7 [70] NA
5W8F FP SAH-MS1-14 Stapled peptide 80 ± 5 [70] NA
5WHI – BCL-1 Apo – [71] NA
5WHH Streptavidin pull-down D-NA-NOXA SAHB Stapled peptide – [71] NA
Estrogen Receptor 2YJD SPR SP1 ERβ/1.99 μM
αER/674
[72] NA
2YJA SPR SP2 ERβ/632
αER/352
[72] NA
5DXB SPR SRC2-SP1 530 [73] NA
5HYR SPR SRC2-SP2 42 [73] NA
5DX3 SPR SRC2-SP3 39 [73] NA
5DXE SPR SRC2-SP4 – [73] NA
5DXG SPR SRC2-SP5 – [73] NA
2LDA – SP2 – NA [72]
2LDC – SP1 – NA [72]
2LDD – SP6 ERβ/155
αER/75
NA [72]
5WGD – SRC2-LP1 – [74] NA
5WGQ – SRC2-BCP1 – [74] NA
Aurora-A 5LXM ITC Stapled TPX2 peptide 10 0.18 μM [73] NA
Tankyrase-2 5BXO FP Cp4n2m3 0.6 ± 0.01 μM [55] NA
5BXU FP Cp4n4m5 2.8 ± 0.1 μM [55] NA
Grb7 5D0J SPR G7-B4NS peptide 4.93 ± 0.03 μM [56] NA
5EEL SPR G7-B4 peptide 0.83 ± 0.006 μM [56] NA
5EEQ SPR G7-B1 peptide 1.5 ± 0.01 μM [56] NA
Replication proteinA 4NB3 FP Peptide-33 0.022 ± 0.005 μM [75] NA
eIF4E 4BEA SPR sTIP-04 Stapled peptide 5 ± 0.7 [58] NA
FP 11.5 ± 3.6
β-catenin 4DJS FP aStAx-35 13 ± 2.0 [76] NA
hDcn-1 3TDZ ITC hCul1WHB: hDcn1P: Acetyl-hUbc121–12(5:9 Staple) 0.15 μM [77] NA
Insulin 3KQ6 Receptor Binding Assays [HisA4, HisA8] insulin IGF-1R/0.05 ± 0.01
IR/125 ± 18
[54] NA
ks-vFLIP 5LDE ITC spIKKƔ-Stapled peptide 30.4 ± 3.8 μM [52] NA
TLE1 5MWJ ITC Peptide18 522 ± 39.6 [59] NA
human IgG1 Fc 5U66 SPR LH1 ~1 ± 0.5 mM [57] NA
CaV β subunit 5V2P ITC AID-CAP Stapled peptide 5.1 ± 1.6 [78] NA
5V2Q ITC AID-CEN Stapled peptide 5.2 ± 1.5 [78] NA
NCOA1 5Y7W – YL-2 – [79] NA
Saccharomyces cerevisiae 5NXQ FP Sld5 CIP A2 0.32 ± 0.02 μM [80] NA
4HU6 – GCN4-p1(7b) – [81] NA
CRPs (Plants) 5NGN – Lyba2 – [82] NA
HIV-1 4NGH – SAH- MPER(671-683KKK)(q)pSer – [13] NA
4NHC – SAH-MPER(671-683KKK)(q) – [13] NA
4U6G – SAH-MPER(662-683KKK)(B,q) [13] NA
8HVP – Ua-I-OH 85548e – [83] NA
7HVP – JG-365 – [84] NA
2L6E Total buried surface NYAD-13 1 μM NA [85]
2JUK – GNB – NA [86]
1ZJ2 – HIV-1 frameshift site RNA – NA [87]
1PJY – HIV-1 frameshift inducing stem–loop RNA – NA [88]
Brevibacillus Bacteria 4OZK – LS – [89] NA
Zebraﬁsh MDM2/X 4N5T Biacore ATSP-7041 MDM2/0.91
MDMX/2.31
[35] NA
Plasmodium falciparum 4MZJ – pGly[801–805] – [90] NA
4MZK – pGly[807-811] – [90] NA
4MZL – HSB myoA – [90] NA
XRMV 4JGS – ɣ-XMRV TM retroviral fusion protein – [91] NA
MPMV 4JF3 – β-MPMV TM retroviral fusion protein – [91] NA
Salmonella 1Q5Z – SipA – [92] NA
(continued on next page)
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Table 2 (continued)
Target PDB ID Binding Assay Peptide Kd (nM) Ref.
X-ray NMR
Synthetic collagen 3P46 – SS1 – [93] NA
EphA2-Sam/Ship2-Sam complex 6F7M MST S13ST Ship2-Sam/52.2 ± 0.7 μM NA [94]
6F7N MST S13ST (short) Ship2-Sam/No binding NA [94]
6F7O MST A5ST Ship2-Sam/No binding NA [94]
Human Cul3-BTB 2MYL FP Cul349-68EN 620 ± 177 NA [95]
2MYM FP Cul349-68LA 305 ± 100 NA [95]
SIV 2JTP – RNA stem-loop – NA [96]
α-helical hairpin proteins 1EI0 – P8MTCP1 – NA [97]
De novo proteins 2M7C – Cp-T2C3b – NA [98]
2M7D – (P12W)-T2C16b – NA [98]
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the protein surface residues: Leu54, Phe55, Gln59 and Met62. This
mode of binding was similar to previously reported structure PDB:
3V3B (described in Section 4.1) indicating that both staples are sited
at the rim area of the p53-binding pocket, where Phe55 is the most im-
portant residue (Fig. 13b). The proteolytic stability, cellular uptake and
toxicity of E1 peptide were evaluated, in which it showed high stability
in a chymotrypsin assay, signiﬁcant cellular permeability observed by
confocal microscopy and did not show non-speciﬁc toxicity as deter-
mined in an LDH leakage assay.
4.3. Speciﬁc MCL-1 Stapled Peptide Inhibitor as Apoptosis Sensitizer in Can-
cer Cells
The members of BCL-2 family known to have an anti-apoptotic role
in cells are considered to be key pathogenic proteins in human diseases
categorized by uncontrolled cell survival - such as cancer and autoim-
mune disorders. The MCL-1 protein belongs to this family and supports
cell survival by trapping the apoptosis- inducing BCL-2 homology do-
main 3 (BH3) α-helix of pro-apoptotic BCL-2 family members. Cancer
cells utilize this physiological phenomenon by overexpressing anti-
apoptotic proteins to guarantee their immortality. As a result, develop-
ing an inhibitor to block the hydrophobic pocket of the anti-apoptotic
proteins from binding the BH3 α-helix could lead to the discovery of a
successful drug. By mimicking BH3 α-helix, several small molecules
compounds were synthesized to inhibit anti-apoptotic proteins and
some are undergoing clinical trials (including ABT-263, obatoclax, and
AT-101).Most target three ormore anti-apoptoticmember proteins, ex-
cept the ABT-199 small molecule inhibitor, which has a high potency
and speciﬁcity to the BCL-2 protein with a Ki b 0.010 nM. ABT-199
was discovered through reverse engineering of navitoclax and keeping
similar hydrophobic interactions but modifying the electrostatic inter-
action with Arg103 (speciﬁc to BCL-2 not BCL-XL) [101]. Furthermore,
ABT-199 has antitumor activity against different cancers as non-
Hodgkin's lymphoma (NHL) [101], refractory chronic lymphocytic
leukemia (CLL) [102,103], and BCL-2–dependent acute lymphoblastic
leukemia (ALL) [101] in vitro. The same positive results were found
in vivo when ABT-199 was tested on a wide spectrum of xenograft
mouse models harboring human hematological tumor (RS4;11), B cell
lymphoma with the t(14,18) translocation [101] and mantel cell lym-
phoma (MCL) [101,104].
Nonetheless, the topography of the binding groove and the amino
acids residues involved in the protein interaction of BH3 helix deter-
mine the speciﬁcity of the anti-apoptotic protein-binding partner.
Therefore, the need to discover an inhibitor that selectively targets the
interacting surface, which is large and complex, is essential. Walensky
and his group [68] selected MCL-1 as their research target, due to its
survival role in a wide-range of cancers and protein overexpression
that has been linked to the pathogenesis of diverse refractory cancers
(including multiple myeloma, acute myeloid leukemia, melanoma and
poor prognosis breast cancer [105–108]). This group was able tosynthesize a highly potent stapledpeptide (MCL-1 SAHBD),which selec-
tively binds MCL-1 and prevent it from suppressing the apoptosis path-
way and sensitizing caspase-dependent apoptosis within cancer cells. A
library of stapled alpha-helices of BCL-2 domain peptides was synthe-
sized based on the BH3 domain of human BCL-2 family and stapling
was located at the i,i + 4 positions using ring-closing metathesis
(RCM). To deﬁne the binding and speciﬁcity of BH3 helix and MCL-1
alone, alanine scanning, site-direct mutagenesis and staple scanning
were performed; the results indicated that MCL-1 SAHBD has the
highest helicity ~90% and strongest binding,with a Kd of 10 nMas deter-
mined by an FP assay. The complex structure of the stapled peptidewith
MCL-1ΔNΔC was solved at 2.3 Å resolution (PDB 3MK8) and showed
that MCL-1 SAHBD is present in a helical conformation and interacts
with the MCL-1 canonical BH3-binding pocket. The peptide α-helix
conserved residues L213, V216, G217, and V220 make a direct hydro-
phobic contact with the MCL-1 interface that is consistent with many
BH3 domains. These hydrophobic interactions are reinforced by a salt
bridge between MCL-1 SAHBD Asp218 and MCL-1ΔNΔC Arg263
(Fig. 14). Interestingly, the hydrocarbon staple with alkene cis confor-
mation made a distinct hydrophobic contact with the edge of the
MCL-1 binding site.Moreover, themethyl group explores a groove com-
prising Gly262, Phe318, and Phe319 of MCL-1 and additional contact
was found between the staple aliphatic side chain and the edge of the
main interaction site (Fig. 15). All of these structural evidence indicate
the role of the staple in the high afﬁnity binding of the peptide and its
ability to provide biological speciﬁcity toward MCL-1. This group also
demonstrated the capacity of MCL-1 SAHBD to effectively sensitize mi-
tochondrial apoptosis in vitro using wild type and Bak−/−mitochon-
dria mouse models and in OPM2 cells by measuring the dissociation of
native inhibitory MCL-1/BAK complexes using FP assay. In comparison
to ABT-199, the MCL-1 SAHBD stapled peptide shows good cell perme-
ability and has the capacity to sensitize cancer cells to apoptosis when
tested on Jurkat T-cell leukemia and OPM2 cells, underscoring the clin-
ical relevance of these ﬁndings. However, theMCL-1 stapledpeptide has
not yet been evaluated in clinical trials.
4.4. Stapled Peptides SP1, SP2 Inhibit Estrogen Receptor ERβ
Estrogen receptor (ER) is a steroid hormone receptor that belongs to
the nuclear receptor (NR) superfamily class. In addition to the receptor's
role in reproduction regulation, ER has a regulatory role in other path-
ways in different systems such as the central nervous system, mainte-
nance of bone density and immunity. Thus, ER is an attractive target
for diseases primarily in breast cancer, endometrial cancer and osteopo-
rosis [109–111]. Structurally the receptor existed in two isoforms (ERα
and ERβ), inwhichboth have a similar domain organization - namely an
N-terminal transactivation (AF1) domain, a well-conserved DNA bind-
ing domain, and a C-terminal ligand-binding domain (LBD). Dependent
upon the bounded ligand, the ER receptor has two different states
that induce changes in the structure, stability and interaction of the
LED with a co-activator protein. When ER is in an agonist-bound
Table 3
The binding role of the staples in X-ray structures from RCSB-PDB.
Target PDB
ID
Peptide Cyclisation Method Kd (nM) Staple Interaction Ref.
Human MDM2 IYCR p53-WT Residues
(15–29)
– 600 – [61]
3V3B SAH-p53-8 Stapled
peptide
RCM/i,i + 7 position 55 Hydrophobic contacts with Leu54, Phe55, Gly58,
and Met62 of MDM2
[62]
4UMN M06 Stapled peptide RCM/i,i + 7 position 63 ± 17.8 Hydrophobic contacts with Leu54, Phe55 and more
closely with Gly 58 of MDM2
[63]
5AFG E1 Stapled peptide CuAAC cycloaddition
“Click-reaction”
7.5 ± 0.7 Hydrophobic contacts with Leu54, Phe55, Gln59
and Met62 of MDM2
[64]
4UE1 YS-1 Stapled peptide RCM/i,i + 4 position 9.9 ± 1.5 None [65]
4UD7 YS-2 Stapled peptide RCM/i,i + 4 position 7.4 ± 1.5 None [65]
5XXK M011 Stapled peptide RCM/i,i + 7 position 6.3 ± 2.9 Hydrophobic contacts with Leu54, Phe55 and more
closely with Gly 58 of MDM2
[66]
Zebraﬁsh MDM2/X 4N5T ATSP-7041 RCM/i,i + 7 position Mdm2/0.91
MdmX/2.31
Van der Waals contacts with Lys47, Met50, His51,
Gly54, Gln55, and Met58 of MDMX
[35]
MCL-1/BCL-2 3MK8 MCL-1 SAHBD Stapled
peptide









RCM/i,i + 4 position 460 ± 232 None [69]
5W89 SAH-MS1-18 Stapled
peptide
RCM/i,i + 4 position 25 ± 7 None [70]
5W8F SAH-MS1-14 Stapled
peptide
RCM/i,i + 4 position 80 ± 5 None [70]
5WHH D-NA-NOXA SAHB
Stapled peptide
RCM/i,i + 7 position – None [71]
Estrogen Receptor 2YJD SP1 RCM/i,i + 4 position 1.99 μM Van der Waals contacts with Val307, Ile310, and
Leu490 of ERβ_LBD
[72]
2YJA SP2 RCM/i,i + 3 position 352 Van der Waals contacts with Val307, Ile310, and
Leu490 of ERβ_LBD
[72]
5DXB SRC2-SP1 RCM/i,i + 4 position 530 None [73]
5HYR SRC2-SP2 RCM/i,i + 4 position 42 None [73]
5DX3 SRC2-SP3 RCM/i,i + 4 position 39 None [73]
5DXE SRC2-SP4 RCM/i,i + 4 position – None [73]
5DXG SRC2-SP5 – – – [73]
5WGD SRC2-LP1 RCM/i,i + 4 position – Hydrophobic contacts between ILe689 and Leu693
with the hydrophobic shelf of ERα
[74]
5WGQ SRC2-BCP1 Cross stitch (oleﬁn &
lactam)/orthogonal position
– Sub-optimal hydrophobic interaction [74]
Aurora-A 5LXM Stapled TPX2 peptide
10
RCM/i,i + 4 position 0.18 μM None [73]
Tankyrase 2 5BXO Cp4n2m3 Double-click Cycloaddition
reaction/i,i + 4 position
0.6 ± 0.01 μM None [55]
5BXU Cp4n4m5 Double-click Cycloaddition
reaction/i,i + 4 position
2.8 ± 0.1 μM None [55]
Grb7 5D0J G7-B4NS peptide RCM+ Thioether/monocyclic
peptide
4.93 ± 0.03 μM None [56]
5EEL G7-B4 peptide RCM+ Thioether/bicyclic peptide 0.83 ± 0.006 μM Close contacts with Met495, Asp496, Asp497
backbone and sidechains of EF loop of Grb7-SH2
and Ile 518 of BG loop
[56]
5EEQ G7-B1 peptide RCM+ Thioether/bicyclic peptide 1.5 ± 0.01 μM Close contacts with Met495, Asp496, Asp497
backbone and sidechains of EF loop of Grb7-SH2
and Ile 518 of BG loop
[56]
Replication protein A 4NB3 Peptide-33 – 0.022 ± 0.005
μM
– [75]
eIF4E 4BEA sTIP-04 Stapled
peptide
RCM/i,i + 4 position FP/11.5 ± 3.6 None [58]
SPR/5 ± 0.7
β-catenin 4DJS aStAx-35 RCM/i,i + 4 position 13 ± 2.0 None [76]
hDcn-1 3TDZ hCul1WHB: hDcn1P:
Acetyl-hUbc121–12
(5:9 Staple)
RCM/i,i + 4 position 0.15 μM None [77]






RCM/i,i + 4 position 30.4 ± 3.8 μM None [59]
TLE1 5MWJ Peptide18 RCM/i,i + 4 position 522 ± 39.6 None [57]
Human
IgG1 Fc
5U66 LH1 RCM/i,i + 7 position ~1 ± 0.5 mM None [78]
CaV β subunit 5V2P AID-CAP Stapled
peptide
m-xylyl linker macrocyclization/i,i +
5 position
5.1 ± 1.6 None [78]
CaV β subunit 5V2Q AID-CEN Stapled
peptide
m-xylyl linker macrocyclization/i,i +
4 position
5.2 ± 1.5 None [75]
(continued on next page)




Peptide Cyclisation Method Kd (nM) Staple Interaction Ref.
Target PDB
ID
Peptide Cyclisation Method Kd (nM) Staple Interaction Ref.
NCOA1 5Y7W YL-2 RCM/i,i + 4 position – None [79]
Saccharomycs cerevisiae 5NXQ Sld5 CIP A2 Double-click Cycloaddition reaction
(CuAAC)/i,i + 6 position
0.32 ± 0.02 μM None [80]
4HU6 GCN4-p1(7b) Oxime bridge (covalent
cross-link)/i,i + 4 position
– Internal polar contact between Gln4 and the U5
carbonyl of the oxime bridge.
[81]
HIV-1 4NGH SAH- MPER
(671-683KKK)(q)pSer
RCM/i,i + 4 position (R3-S5) – None [13]
4NHC SAH-MPER(671-683KKK)
(q)
RCM/i,i + 4 position (R3-S5) – None [13]
4U6G SAH-MPER(662-683KKK)
(B,q)
RCM/i,i + 4 position (R3-S5) None [13]
Plasmodium falciparum 4MZJ pGly[801–805] RCM/i,i + 4 position – Hydrophobic contact with Trp171 and Asp173 [90]
4MZK pGly[807-811] RCM/i,i + 4 position – Hydrophobic contact with Phe148, Leu168, Leu175
an Ile202
[90]
Synthetic collagen 3P46 SS1 Double-click Cycloaddition reaction





6F7M S13ST RCM/i,i + 4 position Ship2-Sam/52.2
± 0.7 μM
None [94]
Human Cul3-BTB 2MYL Cul349-68EN RCM/i,i + 4 position 620 ± 177 None [95]
2MYM Cul349-68LA RCM/i,i + 4 position 305 ± 100 None [95]
De novo proteins 2M7C Cp-T2C3b Gly-Gly linker – None [98]
2M7D (P12W)-T2C16b Gly-Gly linker – None [98]
274 A.M. Ali et al. / Computational and Structural Biotechnology Journal 17 (2019) 263–281conformation, a coactivator protein binding-groove is formed, con-
versely in the antagonist-bound conformation; the groove is lost. The
co-activator binding-site is mediated by a short leucine-rich pentapep-
tide, with the amino acid consensus sequence LXXXLL, known as the
NR box. This peptide was found to form amphipathic α-helices, in
which the three conserved leucine residues are on the hydrophobic
face that binds to the coactivator-binding groove. On the other side of
the binding site, the receptor surface has charged recognition residues




Fig. 11. Alignment of the SAH-p53-8 peptide (yellow, PDB 3V3B) and the native p53
peptide (cyan, PDB 1YCR). The MDM2 molecule is shown in surface representation.
SAH-p53-8 peptide mimics the three pharmacophore residues (Phe19, Leu26, Trp23) in
the binding site in a similar manner to the native p53. The residues outside the Phe19-
Leu26 regions are not visible, indicating conformational ﬂexibility in the bound state.
Moreover, the whole helix of stapled peptide moves by ~1 Å and is rotated by 18°,
allowing the Trp23 indole ring to form a hydrogen bond with MDM2 Leu54 (green line).
Interestingly, Leu26 orientates itself in a distinct manner to that of the native p53 Leu26,
(moving by 2.7 Å toward the N-terminus of the peptide) and the side chain is ﬂipped by
approximately 180° to ﬁll the same pocket space. This feature is not found in any other
reported structure. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)clamp. Modeling of peptide inhibitors that bind to ER and work alloste-
rically could create a new class of NR-regulating drugs. Phillips and his
group [72] designed and synthesized a series of these peptides, aiming
to bind and inhibit ER as pharmacological candidates. Two stapled
peptides known as SP1 and SP2 showed increased helicity as judged
by CD. SP1 showed ~4 fold stronger binding to ER when compared
to unstapled peptides with a Kd of 1.99 μM, while SP2 peptide gave
2-fold increase in binding relative to SP1 (Kd of 352 nM), as deter-





Fig. 12. A closer view of the SAH-p53-8 stapled peptide in a “closed” conformation
state. The MDM2 molecule is shown in surface representation, the peptide (yellow)
and the staple (orange) in sticks. A hydrogen bond is formed between the indole
nitrogen atom of the peptide helix and the carbonyl oxygen of Leu54 of MDM2
(green line). This H-bound is protected from solvent competition by the staple that
lied directly over Met50-Lys64 helix (the rim of p53 binding site). In addition, the
staple intimately interacts with the protein surface and forms an extended
hydrophobic interface with Leu54, Phe55, Gly58, and Met62 of Mdm2. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
a)





















Fig. 13. The E1-MDM2 complex high-resolution structure at 1.9 Å. a) top viewof E1 stapled peptide (magenta, PDB 5AFG) alignedwith the native peptide p53 (cyan, PDB 1YCR), revealing
the typical mode of binding within the MDM2 hydrophobic pocket (grey surface) - placing the triad residues responsible for binding (P2he19, Trp23, Leu26) in the correct orientation to
engage the MDM2 hotspots. The staple is found in anti regioisomer form and interacts with protein surface a similar mode as b) previously reported hydrocarbon SAH-p53-8 stapled
peptide (PDB 3V3B), in that the stapled form four hydrophobic interactions with MDM2 surface residues (Leu54, Phe55, Gln59 and Met62, lime green), in which Phe55 is the most
critical residue. The superimposition of the triazole-stapled E1 peptide with the correlated hydrocarbon-stapled p53 peptide (yellow, PDB 3V3B) suggests that both staples engage the
same area that is located at the rim of the p53 binding pocket, on the Met50–Lys64 helix. The E1 stapled peptide is also shown in 2D for clarity (right). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
275A.M. Ali et al. / Computational and Structural Biotechnology Journal 17 (2019) 263–281the same manner within the co-activator binding-site as shown by
high-resolution structures at 1.9 Å for SP1 ERβ structure (PDB 1YJD),
and 1.8 Å for the SP2 ERα structure (PDB 2YJA). The conserved NR
box LXXLL recognition motif was replaced with the IXXS5L motif in
SP1; as expected the recognition site does not bind in the groove. Al-
ternatively, the i,i + 4 hydrocarbon staple “at S5 position of the motif”
was linked to the SP1 helix by RCM, which made comprehensive van
der Waals contacts with the hydrophobic residues Val307, Ile310, and
Leu490 of the co-activator protein binding groove (Fig. 16). As in the
SP1 ERβ structure, the same interactions for the staple with the hy-
drophobic groove of the coactivator site were found in the SP2 ERα
structure (Fig. 16). The reported structures demonstrate the impor-
tance of designing stapled peptides that inhibit NRs and PPIs in
which stapling not only reinforces the helix conformational but also
promotes staple interaction with the hydrophobic surface of the target
protein. Together this makes stapled peptides promising therapeutic
targets, even for the undruggable targets of traditional small-
molecule inhibitors. A comparison analysis between the stapled pep-
tides SP1, SP2 and an earlier reported NR co-activator peptide 2 in
complex with ERα (PDB 2QGT) revealed a quarter turn of the SP1
helix that shifts the binding site residues by one position in the refer-
ence recognition site (Fig. 17a). However, the SP2 stapled peptide
showed conformational changes of Asp538 and Ile358 residues on
the receptor site in contrast to the co-activator peptide 2. In SP2residue Asp538 rotates in toward the peptide, while it moves out in
the co-activator peptide structure to adjust the Ile side chain into
the peptide-binding motif. Furthermore, Ile358 of the SP2 peptide
adopts a distinct rotamer and packed closer than the second Leu of
the coactivator peptide 2, which in turn allows the staple to span
over the C-terminal recognition motif with a 100° rotation toward
the other side of the protein IL__LL contact site (Fig. 17b).
5. Computational Approach for Staple Peptide Design
Hydrocarbon stapled peptides are at a relatively early stage of devel-
opment. Over the last decade important information about the effects of
staple position, staple structure, and peptide sequence on the activity of
stapled peptides have become available [65]. Most of the reported sta-
pled peptides in the literature have classically been designed based ei-
ther on previous high-resolution structures or comprehensive alanine
scanning studies [5,112]. On the other hand, staple positioning is usually
optimized via chemical synthesis and biophysical characterization of
every possible variant of a peptide construct. However, these methods
are by nomeans comprehensive and provide little insight about the be-
havior of a stapled construct in living cells [113]. Moreover, experimen-
tal characterization of the stapled peptides is neither economically
viable nor feasible within a reasonable timeline, especially for long pep-
tides, and is considered tedious and expensive [65,113].
Fig. 14. The crystal structure of MCL-1 SAHBD stapled peptide (slate helix) binding to the
MCL-1ΔNΔC (light pink surface) interface at the canonical BH3-binding groove, solved at
2.3 Å resolution (PDB 3MK8). The peptide makes several hydrophobic interactions,
including the hydrophobic residues Leu213, Val216, Gly217, and Val220 of MCL-1
SAHBD making direct contact with a hydrophobic cleft at the surface of MCL- 1ΔNΔC
(hot pink). The hydrophobic interaction are reinforced by a salt bridge between MCL-1
SAHBD Asp218 and MCL-1ΔNΔC Arg263 (blue) and these residues also contribute to a
hydrogen bond cluster that includes MCL-1ΔNΔC Asp256 and Asn260 (green). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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stapled peptide design process, because they help to rationalize practi-
cal/experimental observations, provide insight into molecular mecha-
nisms of binding, and identify promising candidate peptides, thus
reducing the need for extensive screening of peptide libraries. At the
same time, utilizing allows to efﬁciently build and characterize peptide
candidates in silico. Thus, we are able to explore each possible staple lo-
cation along the peptide backbone in order to ensure that each candi-
date is considered in the search. All of these advantages reduce costs
and time that are necessary to design and optimize the lead stapledpep-
tide for detailed experimental studies [65,113].
Several computational methods or techniques have been employed
in stapled peptide design, including Energy minimization, Monte Carlo
(MC) simulation and Molecular dynamics (MD) [65].Phe318
Phe319
Gly262
Fig. 15. The hydrocarbon staple of MCL-1 SAHBD peptide with an alkene functionality in
the cis conformation (yellow stick) makes distinct hydrophobic contacts with the MCL-
1ΔNΔC binding site border (light pink surface). A methyl group of the α,α-dimethyl
functionality engages with a groove consisting of MCL-1ΔNΔC Gly262, Phe318, and
Phe319 residues (raspberry sticks). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)An example of a successful computational approachwas the CCmut3
stapled peptide, a Bcr-Abl kinase agonist that effectively reduces the on-
cogenic potential of Bcr-Abl. By applying different in silico tools such as
Chimera [114], AmberTools15 [115] and hydrogen mass repartitioning
(HMR) for accelerating molecular dynamics (MD) simulations
[113,116]; the authors were able to explore 64 peptide analogues with
different possible positions of staple along peptide backbone. Such
models can be used to characterize a wider range of possibilities than
was possible experimentally, due to CCmut3 peptide length, which is
considered long. Additionally, the length of the peptide introduces a
high degree of conformational variability and opportunity to be targeted
by intracellular proteolytic mechanisms. The authors concluded that
computational methods can play a key role in the design process of
therapeutics peptides, speciﬁcally in exploring an exceptionally large
and diverse set of candidates in a short timeframe compared to experi-
mental settings [113].
6. Conclusion
Inhibiting protein-protein interactions (PPI) has become a general
strategy for interpreting the molecular logic associated with PPI net-
works, or for therapeutic applications. The later approach was explored
extensively over the last ten years by introducing a new class of targeted
inhibitors known as hydrocarbon-stapled peptides. Peptides originating
from livestock and biological sources have low stability, short half-life
and unstable secondary-structures due to their sensitivity toward pro-
teolysis [1,16]. These impact peptide bioavailability and binding to
their intracellular target interfaces, making peptides a poor drug candi-
date. However, small molecules are successful drug candidates due to
their size, oral bioavailability and cell penetration. In addition, small
molecules are more appropriate for small and compact protein inter-
faces with a size range of 300–1000 Å [8] such as, BCL2 & BCL-xL pro-
teins (Fig. 18a) [117], p53-MDM2 (Fig. 18b) [62,118] and Hsp90
[119,120] (Fig. 18c). Selected examples of these fruitful small-
molecules drugs are Obatoclax (GS-01570) which entered Phase II clin-
ical trials in patients with small-cell lung cancer [121–124]; Nutlin and
its derivatives [125] led to the evolution of RG7112 as a ﬁrst MDM2 in-
hibitor that entered clinical trials in advanced solid tumor patients in
2007. This was followed by RO5503781 that entered Phase I clinical tri-
als in patients with advanced malignancies in 2011 and ended in 2014
(https://clinicaltrials.gov/ct2/show/record/NCT01462175). A last exam-
ple is a natural product (Geldanamycin (GM) (Fig. 18c)), which was the
ﬁrst molecule to inhibit Hsp90. Geldanamycin entered clinical trials and
its clinical derivative, 17-AAG, reached phases I and II trials in patients
with multiple myeloma, lymphoma, stage IV pancreatic cancer, non-
small-cell lung cancer and solid tumors [126].
Despite the success of small-molecules to perturb different
PPIs, these traditional inhibitors are not sufﬁcient to cover large
interfaces, which are more likely amenable to peptidomimetics.
Subsequently, synthetic and medicinal chemistry developments
delivered stapling as a technique to overcome the limitation of na-
tive peptides in stability, resistance to proteolysis degradation,
speciﬁcity to targets and cell penetration. Depending on the size
of the targeted interface, the afﬁnity of the interaction and
the position of hot spots residues, different strategies have
been generated to synthesize stapled peptides targeting major
PPIs interfaces of previously undruggable protein networks. All-
hydrocarbon stapled peptides lead to the discovery of new candi-
date drugs, combining the advantages of small-molecules and bio-
logics. Examples of these interfaces are p53-MDM2/MDMX, BCL-2
family including MCL-1 BH3 domain, Estrogen receptor, Human
immunodeﬁciency virus type 1 (HIV-1), kinases and Growth fac-
tor. As a result, stapling has found a unique therapeutic niche as
an important class in the pharmaceutical ﬁeld. Furthermore, sci-
entiﬁc technology innovation and novel chemistry methodologies









Fig. 16. The crystal structures of the SP1 ERβ (PDB 1YJD) and SP2 ERα (PDB 2YJA) complexes at 1.9 and 1.8 Å resolution, respectively. Van derWaal interactions (yellow dash lines) were
found between both staples of SP1 and SP2 peptides and the hydrophobic residues on the surface of the co-activator binding site Val307, Ile310 and Leu490. ERβ and ERα proteins are
shown in surface representation, while the staple of the both peptides and the interacting residues are in sticks. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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screening and computational biology will continue to support
peptide drug discovery. It has been found that stapling increased
peptide helicity and reinforces the α-helix conﬁrmation as
shown in several studies, as well as enhancing speciﬁcity and
binding afﬁnity to the targeted protein interface [58,62,65,68,71].
However, some obstacles need to be overcome to improve thera-
peutic properties, such as cellular penetration. In this case, new
peptide drug delivery and formulation approaches are necessary
for this unique class of drugs, although some peptides show high
permeability by endocytosis by optimizing helicity %, PI and hy-
drophobicity together [127]. Consequently, future studies should
focus on the factors that promote cellular uptake and endosomal
release in stapled peptide design. Another challenge that must
be overcome is the oral availability of peptide therapeutics,
which could be boosted by increasing drug stability in the gastro-
intestinal tract, again by formulating peptide penetration with en-
hancers or congregating with carrier molecules or nanoparticles
[128–130]. Finally, in some cases, stapled peptides with higha)
Fig. 17. Comparison analysis of a) SP1 (lime green helix) and b) SP2 (aquamarine helix) stapled
PDB 2QGT). a) SP1 stapled peptide exhibited a quarter turn with respect to the co-activator pep
differently and packs tighter than the coactivator peptide 2 does. Additionally, two residues in t
SP2 helix to the C-terminus site of the recognitionmotif that is rotated by 100° toward the other
ﬁgure legend, the reader is referred to the web version of this article.)afﬁnities do not necessary translate to the target cell, as
Wallbrecher and Okamoto demonstrated when applying stapling
to BimBH3 peptides to bind BCL-2 proteins and induce apoptosis
[131,132]. In agreement, PPI antagonists are usually evaluated
using in vitro biochemical and biophysical assays like ﬂuorescence
polarization (FP), surface plasmon resonance (SPR) [25,29,133],
isothermal calorimetry (ITC) [32], enzyme-linked immunosorbent
assay (ELIZA) [134] and ﬂuorescence or bioluminescence reso-
nance excitation transfer (FRET/BRET) [135,136] to quantify their
binding potency and ability to disrupt the targeted PPI. Even
with the availability of ﬂuorescent image-based assays such as
the proximity ligation in situ assay (P-LISA) [137,138] and two/
three hybrid (F2H and F3H) assays [99,139] to assess PPI antago-
nists in real-time within the cells; none can reveal whether
these antagonists can cross the cell membrane effectively in a na-
tive intracellular environment. To overcome this issue, the ReBiL
platform has been developed by Li and co-workers to detect
weak PPI interactions and mechanisms of drug action in living
cells. It has been successfully applied on antagonists of p53:b)
Asp538
Ile358
peptides in relation to previously reported NR co-activator peptide 2 (lightmagenta helix,
tide locating the hydrophobic staple to the recognition site position. While b) SP2 rotates
he receptor site (Asp538 and Ile358) induce conformational changes bridging the staple of
side of the protein IL__LL contact site. (For interpretation of the references to colour in this
a)
b)                                                                                     c)
Fig. 18. Crystal structures of successful small molecules inhibiting drug-target PPIs that have entered clinical trials. a) ABT-737 (pink sticks) binds to BCL-xL (PDB 2YXJ) with nanomolar
binding afﬁnity, b) Nutlin-2 (green sticks), is one of the ﬁrst identiﬁed potent MDM2–p53 inhibitors and is shown bound to the N-terminal domain of MDM2 (PDB 1RV1) and
c) geldanamycin (GM) (light blue stick) in complex with Hsp90 (PDB 1YET), considered the ﬁrst Hsp90 inhibitor to enter clinical trials. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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peptides (SAHBp53-8, ATSB-7104 and sMTide-02). They revealed
that potent binding in vitro does not necessarily correlate with
higher intracellular PPI disruption activity. This emphasizes the
importance of using an assay like ReBiL to analyze directly the dis-
ruption of target PPI within cells [140].
Interestingly, relatively few reported high-resolution structures of
stapled peptide in complex with their target interface reveal a direct in-
teraction between the staple itself and residues of the protein interfaces
(Table 2). A phenomenon is observed with the MCL-1 SAHBD/MCL-1,
SAH-p53-8/MDM2, E1/MDM2, SP1/ERβ and SP2/ERα complexes, in
which staples make additional hydrophobic interaction with protein
surface residues that ﬁx the peptide in a bound state within the target
pocket. Additionally, the staple can play a role in peptide penetration
and bioactivity [127].
Taken together, hydrocarbon-stapled peptides are a fertile ground
for drug discovery. However, the development of highly cell-
permeable and bioactive peptides is a challenging task that includes
several phases. Starting from the correct design of the peptide,
screening of different stapling positions and/or point mutations, mea-
suring binding afﬁnities and testing speciﬁcity toward the target pro-
tein interface, structural and computational analysis should be
performed in order to understand how the peptide and/or staplebinds and which interactions are involved. Importantly, two ques-
tions need to be tackled in current research: Firstly, can a stapled
peptide with signiﬁcant in vitro results penetrate the cell membrane
toward the target PPI complex? Secondly, if it reaches the target PPI,
will this peptide exert the expected bioactivity in vivo? This question
could be addressed with future research aiming to tailored bioactive
therapeutic peptides with high permeability and increased precision
to PPIs within the targeted cell using advanced medicinal and syn-
thetic chemistry in parallel with computational and drug delivery
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